Interleukin-6 Is a Significant Predictor of Radiographic Knee Osteoarthritis

The Chingford Study

Gregory Livshits,1 Guangju Zhai,2 Deborah J. Hart,2 Bernet S. Kato,2 Huizhong Wang,3 Frances M. K. Williams,2 and Tim D. Spector2

Objective. There is a great need for identification of biomarkers that could improve the prediction of early osteoarthritis (OA). We undertook this study to determine whether circulating levels of interleukin-6 (IL-6), tumor necrosis factor α (TNFα), and C-reactive protein (CRP) can serve as useful markers of radiographic knee OA (RKOA) in a normal human population.

Methods. RKOA data were obtained from the cohort of the Chingford Study, a prospective population-based study of healthy, middle-aged British women. The RKOA-affected status of the subjects was assessed using the Kellgren/Lawrence (K/L) grade as determined on radiographs obtained at baseline (n = 908) and at 10 years and 15 years thereafter. Serum levels of CRP, IL-6, and TNFα were assayed at 5, 8, and 15 years, using high-sensitivity commercial assays. A K/L grade of ≥2 in either knee was used as the outcome measure. Statistical analyses included analysis of variance for repeated measurements and logistic regression models, together with longitudinal modeling of dichotomous responses.

Results. During 15 years of followup, the prevalence of RKOA (K/L grade ≥2) increased from 14.7% to 48.7% (P < 0.00001 versus baseline). The body mass index (BMI) and circulating levels of CRP and IL-6 were consistently and significantly higher in subjects diagnosed as having RKOA. When multiple logistic regression was applied to the data, the variables of older age (P = 3.93 × 10−5), higher BMI at baseline (P = 0.0003), and increased levels of IL-6 at year 5 (P = 0.0129) were determined to be independent predictors of the appearance of RKOA at year 10. The results were fully confirmed using longitudinal modeling of repeated measurements of the data obtained at 3 visits. The odds ratio for RKOA in subjects whose IL-6 levels were in the fourth quartile of increasing levels (versus the first quartile) was 2.74 (95% confidence interval 1.94–3.87).

Conclusion. This followup study showed that individuals were more likely to be diagnosed as having RKOA if they had a higher BMI and increased circulating levels of IL-6. These results should stimulate more work on IL-6 as a potential therapeutic target.

Osteoarthritis (OA) is the most common form of arthritis and can result in substantial morbidity and disability in the elderly (1). It is known that OA imposes a great economic burden on modern society (2,3). Risk assessment or diagnosis at the early stages of the disease, coupled with the development of preventive or therapeutic interventions, could substantially improve the quality of life for the elderly and reduce health care costs. The development of preventive strategies and early-stage interventions for OA is likely to depend on identification of the biologic mechanisms and biomark-
ers that underlie progressive deterioration of joint structure and function. However, there are still no commonly accepted and reliable biomarkers for predicting the development and progression of OA and for distinguishing mild, age-related disease from the rarer form of aggressive, rapidly progressive disease.

Since OA is a heterogeneous and multifactorial process of joint degeneration, various mechanisms may be involved in its development. Inflammation is potentially a key mechanism that appears to act through alteration of cytokine profiles, which occurs secondary to aging of the immune system or obesity (4–7). Interleukin-1β (IL-1β) and tumor necrosis factor α (TNFα) are of special interest in the elderly, because both cytokines induce production of IL-6 and because they have profound effects on body metabolism, body composition, and the acute-phase response (8–10), all of which are altered with increasing age. TNFα has been shown to regulate energy expenditure in humans during inflammation and is associated with low lean body mass, which is an important marker of physiologic status and a major predictor of survival, strength, and functional status in the elderly (11).

The role of IL-6 in inflammation differs from that of TNFα. The levels of IL-6 are elevated in a variety of inflammatory conditions (12) and in bone resorption (13). However, IL-6 does not cause symptoms of inflammation when infused at high doses, but rather it suppresses the synthesis of other inflammatory cytokines (14) and causes hepatic production of acute-phase proteins such as C-reactive protein (CRP). Increased circulating levels of CRP and IL-6 have been found to be predictors of reduced physical mobility (15) and incident mobility limitation (4) in the elderly. Moreover, there is a growing body of evidence, obtained mostly from cross-sectional studies, suggesting that their levels, especially those of CRP, are elevated in OA (16–18), although results in recent reports have been contradictory (19). To the best of our knowledge, the contribution of inflammatory factors such as IL-6 and TNFα to the severity and incidence of OA has not been examined systematically; in particular, the course of these factors longitudinally over multiple time points has yet to be defined.

The major aim of this study was to explore whether the circulating levels of 3 key inflammation markers, CRP, IL-6, and TNFα, are independently associated with radiographic knee OA (RKOA) in a large cohort of middle-aged European women who were followed up for 15 years. We were also interested in determining whether the effect of these markers is independent of the body mass index (BMI), a known significant predictor of OA (e.g., see ref. 19).

PATIENTS AND METHODS

Study cohort. The participants of this study were white women, and the data for this cohort were collected within the framework of the Chingford Study. This is a well-established, prospective population-based study of middle-aged British women who have been evaluated intensively for OA and osteoporosis since 1989. The cohort originally consisted of 1,003 women ages 45–64 years, selected through general practitioner records. All subjects were recruited from a sample of 1,353 women as part of a health trial; to avoid selection bias, the subjects were not aware of the research into OA. There were no inclusion/exclusion criteria other than age. The cohort has been followed up biannually, and many clinical, anthropometric, psychosocial, radiologic, and metabolic variables have been recorded on at least 2 time points (20,21). The Chingford Study is currently approaching its twentieth year and has retained ~65% of the cohort, with a current age range of 60–82 years. All subjects still participating in the Chingford Study were reexamined for the present study in Chingford Hospital in North-East London.

The radiologic and biochemical factors relevant to the present study included RKOA status obtained from radiographs of both knees, and the serum concentrations of 3 inflammatory cytokines, namely, CRP, IL-6, and TNFα. The radiologic examinations were carried out at year 1 (entry examination [baseline]) and at year 10 and year 15 thereafter. Blood samples were obtained at years 5, 8, and 15. Anthropometric assessments, including determination of the BMI, were carried out at all visits. Table 1 provides details of the study sample for each variable and at each time point during the 15 years of followup.

Identification of RKOA. Anteroposterior extended-view weight-bearing radiographs of the knees were obtained at baseline and at 10 years and 15 years thereafter. Views were standardized for position, with the backs of the knees in contact with the cassette, the patella centralized over the lower end of the femur, and the beam centered 2.5 cm below the apex of the patella, with a tube-to-film distance of 100 cm. Radiographs were read by examiners (DJH and TDS) who were blinded to the clinical information, with the readings checked against an atlas of radiographic features to determine a global Kellgren/Lawrence (K/L) grade of RKOA (scale 0–4) (22) and to evaluate individual features of osteophytes and joint space narrowing (scale 0–3 for both).

A case of RKOA was defined as a K/L grade of ≥2 in either knee. Pairs of knee films were read by a single investigator (DJH or TDS). Reproducibility of this method showed that intraobserver agreement for side-by-side readings was high (κ = 0.88), and reproducibility for detecting change in longitudinal radiographs was also relatively high (κ = 0.79). We found little difference in the reproducibility between blinded readings (intraobserver κ = 0.83, longitudinal κ = 0.70) and side-by-side readings, so the main radiographic analysis was performed with baseline and followup films read side-by-side. In the statistical analysis, we examined the association of the predictor variables with a dichotomous variable.
Serum cytokine levels
hsCRP, mg/liter

| Year 1   | 474 | 0.263 ± 0.099 | 0.143 (21.200–0.012) | 19.703 (0.112) | 0.346 | 0.096 |
| Year 8   | 473 | 3.002 ± 4.319 | 1.560 (30.228–0.307) | 3.654 (0.112) | 0.870 | 0.139 |
| Year 15  | 322 | 1.935 ± 2.386 | 1.267 (20.028–0.162) | 4.451 (0.136) | 0.495 | 0.192 |
| IL-6, pg/ml
Year 5   | 429 | 2.034 ± 3.690 | 0.976 (24.889–0.185) | 4.475 (0.118) | 1.055 | 0.215 |
| Year 8   | 473 | 3.002 ± 4.319 | 1.560 (30.228–0.307) | 3.654 (0.112) | 0.870 | 0.139 |
| Year 15  | 322 | 1.935 ± 2.386 | 1.267 (20.028–0.162) | 4.451 (0.136) | 0.495 | 0.192 |
| TNFα, pg/ml
Year 5   | 430 | 8.367 ± 17.333 | 3.375 (173.798–0.642) | 5.379 (0.118) | 0.904 | 0.151 |
| Year 8   | 473 | 3.596 ± 5.420 | 1.851 (48.061–0.672) | 4.488 (0.112) | 1.399 | 0.172 |
| Year 15  | 322 | 1.496 ± 0.848 | 1.192 (7.136–0.138) | 2.065 (0.136) | 0.305 | 0.195 |

Age, years

| Year 1   | 1,003 | 54.68 ± 6.02 | 54.256 (44–68) | – | – | – |
| Year 10  | 1,002 | 64.46 ± 6.16 | 64.080 (53–78) | – | – | – |
| Year 15  | 645 | 69.12 ± 5.81 | 68.523 (60–82) | – | – | – |

* NS = not significant (P > 0.05); hsCRP = high-sensitivity C-reactive protein; IL-6 = interleukin-6; TNFα = tumor necrosis factor α.
† Mean (SEM) values are the estimate of skewness of the original, nontransformed data, while the Ln_dst represents the results of the test for normality of the distribution of the natural logarithm-transformed data (new estimate of skewness).
‡ Values are the root square multiple-determination correlation coefficient for age or, if significantly associated, age-squared.

Measurement of cytokine levels. Since blood samples were not available for the entire cohort, some data on cytokine levels were missing; the corresponding sample sizes for each variable are given in Table 1. After subjects fasted overnight, blood samples were obtained by venepuncture, and the cells were removed by centrifugation. Serum aliquots were stored at −70°C until analyzed. Serum CRP levels were determined with a high-sensitivity nephelometric method using the Beckman Image Immunochemistry system (Beckman Instruments, Fullerton, CA), which has a minimum level of detection of 0.2 mg/liter. Serum levels of TNFα were measured using a high-sensitivity commercial enzyme-linked immunosorbent assay (ELISA) with an alkaline phosphatase signal amplification system for TNFα (Quantikine High-Sensitivity ELISA, catalog no. STS005D, lot no. 246936; R&D Systems, Minneapolis, MN). Serum levels of IL-6 were measured using an ultrasensitive ELISA kit (hIL-6 Ultra-Sensitivity ELISA, catalog no. KHC0064, lot no. S070617D; BioSource, Nivelles, Belgium). All measurements were carried out in accordance with the manufacturers’ instructions and were implemented using the microplate reader Opsys MR (Dynex, Alexandria, VA). The minimum levels of detection were 0.038 pg/ml and 0.104 pg/ml for TNFα and IL-6, respectively. The intra- and inter-assay coefficients of variation for measurements of CRP, IL-6, and TNFα were 2.6%, 4.6%, and 5.3%, respectively, and 3.1%, 5.4, and 7.5%, respectively.

Table 1. Basic descriptive statistics of the study sample by variable and visit*
The relative effect of the selected potential predictors of the risk of development of RKOA was next examined using logistic regression analysis with multiple predictor variables. This was carried out in 2 stages. First, the dichotomous variable for RKOA-affected status (affected [K/L grade ≥2] versus unaffected [K/L grade <2]) at year 10 was analyzed by standard logistic regression in a model that included quantitative (continuous) variables (age and BMI at entry examination, and cytokine levels measured at year 5) as predictors of risk probability (as well as the odds ratio [OR] with 95% confidence interval [95% CI]). In addition, longitudinal modeling of the dichotomous responses was undertaken using models implemented with the Stata statistical package (version 10; StataCorp, College Station, TX). Similar to the abovedescribed logistic regression analysis, the longitudinal models also tested the risk of RKOA as a function of the predictor variables of interest. The data consisted of longitudinal dichotomous responses, with measurements at years 1, 10, and 15, and data were nested in subjects, which meant that there was dependence among the responses within the same subject.

In addition, a mixed-effects logistic model was used to evaluate the relationship across time (at years 1, 10, and 15) between the presence of RKOA (i.e., K/L grade ≥2) and the continuous predictor variables, including age and BMI, which were collected during the same years as the RKOA data, and the levels of inflammatory cytokines, which were selected in the univariate analyses and assayed at years 5, 8, and 15. This

### Table 2. Comparison of the natural logarithm–transformed cytokine levels by radiographic knee osteoarthritis–affected status and visit*

| Cytokine | Year 1 | Year 10 | Year 15 |
|----------|--------|---------|---------|
|          | Unaffected | Affected | Unaffected | Affected | Unaffected | Affected |
|          | No. of subjects | Mean ± SD | No. of subjects | Mean ± SD | No. of subjects | Mean ± SD |
| **IL-6** |        |         |        |         |        |         |
| Year 5   | 370 | 0.05 ± 0.88 | 57 | 0.55 ± 1.11 | 257 | -0.02 ± 0.88 | 169 | -0.32 ± 0.97 | 154 | -0.03 ± 0.83 | 165 | 0.27 ± 0.98 |
| Year 8   | 412 | 0.56 ± 0.91 | 58 | 0.83 ± 0.79 | 290 | 0.52 ± 0.94 | 180 | 0.70 ± 0.82 | 176 | 0.48 ± 0.95 | 176 | 0.59 ± 0.86 |
| Year 15  | 283 | 0.27 ± 0.78 | 39 | 0.48 ± 0.83 | 200 | 0.22 ± 0.77 | 122 | 0.42 ± 0.81 | 156 | 0.16 ± 0.77 | 156 | 0.39 ± 0.78 |
| **TNFα** |        |         |        |         |        |         |
| Year 5   | 371 | 1.37 ± 1.06 | 56 | 1.41 ± 1.05 | 258 | 1.33 ± 1.06 | 169 | 1.45 ± 1.06 | 155 | 1.34 ± 1.06 | 165 | 1.44 ± 1.13 |
| Year 8   | 412 | 0.79 ± 0.75 | 58 | 1.16 ± 0.87 | 290 | 0.81 ± 0.78 | 180 | 0.88 ± 0.76 | 176 | 0.82 ± 0.81 | 176 | 0.86 ± 0.75 |
| Year 15  | 283 | 0.28 ± 0.50 | 39 | 0.22 ± 0.44 | 200 | 0.27 ± 0.50 | 122 | 0.28 ± 0.47 | 157 | 0.29 ± 0.51 | 156 | 0.26 ± 0.47 |
| **CRP**  |        |         |        |         |        |         |
| Year 5   | 358 | -1.82 ± 1.08 | 56 | -1.45 ± 1.15 | 248 | -1.93 ± 1.02 | 166 | -1.65 ± 1.15 | 146 | -1.94 ± 1.01 | 163 | -1.74 ± 1.14 |
| Year 8   | 409 | -2.01 ± 0.99 | 62 | -1.75 ± 0.94 | 287 | -2.00 ± 1.02 | 184 | -1.94 ± 0.94 | 174 | -1.99 ± 1.02 | 174 | -1.97 ± 0.93 |
| Year 15  | 280 | -1.70 ± 0.99 | 39 | -1.55 ± 0.93 | 198 | -1.77 ± 0.97 | 121 | -1.52 ± 0.98 | 154 | -1.86 ± 0.99 | 155 | -1.51 ± 0.94 |

* IL-6 = interleukin-6; TNFα = tumor necrosis factor α; CRP = C-reactive protein.
† P < 0.05 versus unaffected, by analysis of variance.

compared BMI values collected at years 1, 10, and 15 and cytokine levels collected at years 5, 8, and 15 in individuals with and those without RKOA. All of these statistical analyses were conducted using the Statistica package, version 7 (StatSoft, Minneapolis, MN).

Table 2. Comparison of the natural logarithm–transformed cytokine levels by radiographic knee osteoarthritis–affected status and visit*
IL-6 IN RADIOGRAPHIC KNEE OA

Figure 1. Mean interleukin-6 (IL-6) levels standardized for visit-specific mean and variance (IL6 STD) in 3 radiographic knee osteoarthritis (RKOA) categories: 1 = unaffected (Kellgren/Lawrence [K/L] grade <2), 2 = initial stage of RKOA (K/L grade 2), and 3 = severe RKOA (K/L grade >2). Bars show the 95% confidence intervals. The unadjusted sample sizes were 931, 174, and 101 individuals in RKOA categories 1, 2, and 3, respectively.

RESULTS

Descriptive statistics. The sample characteristics, including the sample sizes for each trait determined at each visit as well as the levels of circulating cytokines and BMI, are provided in Table 1. Not all individuals whose radiographic and BMI data were available could be assayed for cytokine levels. Initial analyses revealed that the data on cytokine levels were not distributed normally, in that values showed significant skewness to the right. These data were therefore subjected to adjustment using natural logarithm transformation, which improved the data distribution substantially (Table 1).

Nine hundred eight individuals with complete data on the K/L grade of RKOA were available at the entry examination, while 2 subjects were lost to followup by year 10, and 293 subjects were lost to followup by year 15. The main reasons for the loss to followup by year 15 included mortality unrelated to RKOA (99 individuals), withdrew from the study (85 individuals), moved to a different address (75 individuals), and unknown reasons (36 individuals). At baseline, 15.3% of subjects reported having knee pain. During followup, the prevalence of RKOA in either knee increased from 14.7% to 37.4% by year 10, and to 48.7% by year 15. The observed change in RKOA prevalence over the 3 visits was highly statistically significant ($\chi^2 = 330.1, 2$ df; $P < 0.00001$ versus baseline, by Friedman’s test). The prevalence of RKOA in each knee, as assessed by K/L grade, was comparable, with a slight excess in the right knee compared with the left knee, with prevalences at baseline, year 10, and year 15 of 11.0% versus 8.8%, 30.9% versus 25.6%, and 42.1% versus 36.3%, respectively. These differences in RKOA prevalence between knees appeared to be statistically significant ($P = 0.042–0.001$ at each visit separately, by Friedman’s test and, especially, by Cochran’s Q test; $P < 0.00001$ for the 3 visits combined).

Circulating levels of each of the 3 cytokines were within the ranges expected for a normal population. The correlations of the circulating cytokine levels with age were all low and, in some instances, statistically nonsignificant (Table 1). There were no significant correlations between the individual measurements of TNFα at different visits; however, mean TNFα levels clearly decreased from year 5 to year 15 ($P < 0.001$) (Table 1). The mean values for CRP and IL-6 showed no clear trend with each followup visit. When individual serum concentrations of CRP and IL-6 were compared between the years, we found low correlations between the IL-6 levels ($r = 0.22–0.24$, $P < 0.01$) and moderate correlations between the CRP concentrations ($r = 0.46–0.48$, $P < 0.001$). Adjusted for age, IL-6 levels correlated significantly with CRP concentrations in all possible pairwise comparisons, with correlations ranging from 0.22 to 0.48 ($P < 0.01$). Of note, there was very little bias resulting from withdrawal from the study, since age, IL-6 levels, and RKOA prevalence rates among those who withdrew were all comparable with the values in the total sample, specifically for RKOA prevalence at baseline ($P = 0.26$) and for the total assayed level of IL-6 at year 5 ($P = 0.94$).

Association between RKOA status and circulating biomarker levels. The mean age, BMI measurements, and IL-6 levels were consistently higher in RKOA-affected individuals than in unaffected individuals, as determined by univariate ANOVAs (Table 2). When the respective data from the 3 visits (for BMI and IL-6 measurements separately) were combined and the implemented ANOVAs were corrected for repeated measurements, the differences between RKOA-affected and unaffected individuals were significant ($P < 0.001$) for both variables. In particular, the circulating levels of IL-6 were substantially higher in individuals with severe RKOA (defined as a K/L grade >2 in either or both knees) (Figure 1). CRP levels were also consistently higher in affected individuals, although the differences in CRP levels between affected and unaffected individ-

[Table 1: Descriptive statistics, including sample sizes and means for various traits such as BMI and IL-6 levels.]
uals did not reach statistical significance in 4 of 9 comparisons. However, when the data from the 3 visits were combined and corrected for repeated measurements, there was a significant trend toward higher levels of CRP in affected individuals ($P = 0.002$ versus unaffected).

BMI, IL-6 levels, and CRP levels, as well as the mean age per time point, were then examined by multiple logistic regression analysis. As shown in Table 3, age and BMI at baseline and IL-6 levels at year 5 were retained in the model as significant predictors of subsequent RKOA at year 10, suggesting that individuals were more likely to be diagnosed as having RKOA if they had a higher BMI at baseline (OR $1.115$, 95% CI $1.051$–$1.184$ per kg/m$^2$) and increased IL-6 levels (logarithm-transformed) at year 5 (OR $1.340$, 95% CI $1.064$–$1.687$ pg/ml).

Finally, longitudinal modeling of repeated measurements using mixed-effects logistic regression analysis confirmed the results obtained by multiple logistic regression (Table 4). In the longitudinal analysis, for the sake of simplicity, determinations of RKOA, age, and BMI at years 1, 10, and 15 and the cytokine measurements at years 5, 8, and 15 were designated visits 1, 2, and 3, respectively. Results were consistent for diverse comparisons of the visits, e.g., visit 1 compared with visit 2, visit 1 compared with visit 3, or all 3 visits compared. The results showed that older age, higher BMI, and increased IL-6 levels were all significant independent predictors of RKOA status, while CRP levels did not make a significant independent contribution.

Figure 2 shows the predicted risk of RKOA at ages 50, 60, and 70 years as a function of BMI and IL-6 levels; i.e., we estimated the probability of the individual having RKOA according to 3 specific categories of BMI ($1 = 21$–$30$ kg/m$^2$, $2 = 31$–$40$ kg/m$^2$, and $3 = 41$–$50$ kg/m$^2$) and according to quartiles of logarithm-transformed mean IL-6 measurements. The interplay observed between IL-6 levels and BMI indicated that at age 50 years, the effect of both BMI and IL-6 levels appeared in only very-obese individuals (those in BMI category 3) (Figure 2A). At age 70 years, the effect was evident in less-obese individuals (those with a BMI of $\leq 30$ kg/m$^2$) (Figure 2C). The effect of IL-6 levels was seen particularly well in this latter group (Figure 2C) and also in individuals at age 50 years whose BMI was $\leq 50$ kg/m$^2$ (Figure 2A). The risk of RKOA clearly increased with increasing IL-6 levels in individuals at age 60 years whose BMI was $\leq 40$ kg/m$^2$ (Figure 2B).

When the effects of IL-6 levels alone were assessed, the comparison of the quartiles showed that the likelihood of being diagnosed as having RKOA in individuals with IL-6 levels in the fourth quartile (versus the first quartile) was 2.74 (95% CI 1.94–3.87; $P < 0.001$) when only individuals with a K/L grade $\geq 2$ were considered. In individuals with severe RKOA (K/L

### Table 3. Multiple logistic regression analysis of significant predictors of radiographic knee osteoarthritis at year 10*

| Effect      | Estimate | Standard error | Odds ratio (unit change) | 95% CI     | $P$    |
|-------------|----------|----------------|--------------------------|------------|--------|
| Intercept   | −7.520   | 1.254          | –                        | 4.5 × $10^{-9}$ |        |
| Age         | 0.076    | 0.018          | 1.079                    | 1.041–1.119 | 3.93 × $10^{-5}$ |
| BMI         | 0.109    | 0.109          | 1.115                    | 1.051–1.184 | 0.0003 |
| Ln_IL-6     | 0.293    | 0.117          | 1.340                    | 1.064–1.687 | 0.0129 |

* Independent variables included age and body mass index (BMI) at baseline and C-reactive protein and interleukin-6 (IL-6) levels at year 5. Only significant results are shown. 95% CI = 95% confidence interval; Ln_IL-6 = natural logarithm-transformed IL-6 levels.

### Table 4. Mixed-effects logistic regression analysis of the significant predictors of radiographic knee osteoarthritis from repeated measurements at years 1, 10, and 15*

| Effect | Visits 1 and 2 | Visits 1 and 3 | Visits 1, 2, and 3 |
|--------|----------------|----------------|-------------------|
|        | Estimate       | Standard error | $P$               | Estimate       | Standard error | $P$               | Estimate       | Standard error | $P$               |
| Intercept | −28.988       | 7.140          | 0.001             | −55.797       | 14.114         | <0.001           | −84.624       | 13.874          | <0.001           |
| Age     | 0.289          | 0.076          | <0.001            | 0.518         | 0.137          | <0.001           | 0.917         | 0.163           | <0.001           |
| BMI     | 0.325          | 0.912          | <0.001            | 0.727         | 0.211          | 0.001            | 0.765         | 0.165           | <0.001           |
| Ln_IL-6 | 0.137          | 0.063          | 0.028             | 1.327         | 0.625          | 0.034            | 1.107         | 0.490           | 0.024            |

* Independent variables included age and BMI at years 1, 10, and 15 and C-reactive protein and IL-6 levels at years 5, 8, and 15 (designated visits 1, 2, and 3, respectively). Only significant results are shown. See Table 3 for definitions.
DISCUSSION

The prevalence of RKOA in this population sample of women whose data were obtained from general practice registers in the UK increased during the 15 years of followup, from 14.7% to 48.7%. We also noted the higher prevalence of OA in the right knee (versus the left), suggesting involvement of mechanical factors in RKOA etiologic development. The novel finding of this study was a consistent association of IL-6 circulating levels with the prevalence and incidence of RKOA as assessed by K/L grade. IL-6 levels were consistently found to be associated with the RKOA prevalence in the specific year and when the 3 visits were combined. Two other variables that were consistent predictors of the appearance of RKOA were age and BMI (Tables 3 and 4).

Although the evidence for an association with serum TNFα levels was negligible, CRP levels were also significantly associated with RKOA when considered separately (Table 2). However, the effect of CRP disappeared after adjustment for age and IL-6 levels in multivariate analysis (Tables 3 and 4), likely because the CRP concentration and the levels of IL-6 are related biologically. In our study, the serum concentrations of CRP and IL-6 showed a significant correlation, which varied between 0.22 and 0.48 ($P < 0.001$), depending on the year of the visit. CRP levels showed very low, nonsignificant correlations with age. This may account for our earlier findings of a significant predictive effect of CRP in the same sample (16). In the present sample, when the IL-6 effect was considered alone, it showed a highly significant association with RKOA ($P < 0.001$). As a result, the prevalence comparison between the first and fourth quartiles of IL-6 levels yielded an OR of 2.74 (95% CI 1.94–3.87; $P < 0.001$) for those with K/L grade $\geq 2$ knees, and an OR of 3.59 (95% CI 1.93–6.68; $P < 0.001$) when only those with severe RKOA (K/L grade $> 2$) were considered.

A growing body of evidence suggests that development of OA, even at the early stages, is often accompanied by inflammation (24). This is consistent with the findings from epidemiologic studies in which the severity and progression of tibiofemoral cartilage damage were observed to be more common and severe in patients having reactive and inflamed synovial fluid (25). Moreover, elevated levels of cytokines such as IL-1β and TNFα, both of which are regulators of inflammation, are found in the disease process, although their precise cell of origin is not clear (17,26). Increased levels of CRP have been associated with the prevalence and progres-
sion of knee and hip OA in several studies (16,18,27), although in other studies, this association became non-significant after adjustment for BMI (19). Of note, however, to our knowledge, there is no published study examining the association between OA and circulating IL-6 levels. Thus, the present study is the first to assess this association.

One potential source of these inflammatory cytokines is adipose tissue, which accompanies obesity (28) and which is known to be associated with high levels of biomarkers of inflammation, including IL-6 (7,29). In the study by Das (29), the results suggest that synthesis of TNFα (and leptin) in adipose tissue could induce the production of IL-6 and the acute-phase reactant CRP. Increased levels of these cytokines may, in turn, contribute to the development of OA. Our data support this observation. In our study, we observed significantly higher BMI values in individuals affected with RKOA. Moreover, the correlation between BMI and RKOA was found not only with the weight-bearing knee joints but also with hand OA in the present sample (results not shown). The link between obesity and hand OA was noted some time ago (e.g., see ref. 30). Although the mechanism remains to be debated, one of the most popular theories is that fat tissue causes systemic release of proinflammatory cytokines. Circulating IL-6, as mentioned above, is known to stimulate CRP production by the liver. Indeed, we observed consistent correlations between the CRP levels and IL-6 levels, and significantly higher CRP levels in RKOA-affected individuals.

There are several limitations to this study. First, there is a discrepancy in the timing of the study assessments of RKOA and the cytokine assays (Table 1). Serum samples were not available at baseline when the first set of radiographs was obtained. Thus, it is not known how many individuals had RKOA at year 5 (when the first serum samples were assayed). Likewise, the number of subjects having elevated IL-6 levels at baseline, when the first radiographic examination was conducted, is not known. This was the main reason for testing the association between the cytokine levels at year 5 with RKOA at year 10.

The second limitation is that inflammatory cytokines were measured in the circulation and not in synovial fluid. It is possible that serum cytokines could originate from a different tissue. In addition, the decreasing sample size with each followup visit, albeit inevitable in a longitudinal study of this kind, did contribute to a loss of statistical power. We found, however, no evidence of a systematic bias resulting from the loss of baseline subjects at followup. First, only a relatively small proportion of the sample was lost during the followup period. Second, IL-6 levels and OA prevalence rates at the baseline examination did not differ between those who subsequently dropped out and the total group.

The effect of limited sample size was pronounced when multivariate analyses were undertaken, since the small sample numbers at baseline would not allow us to specifically examine progressive disease. However, we believe that incidence and progression may be interchangeable in this kind of study. For example, since we defined RKOA as a K/L grade ≥2 in either knee, those with a K/L grade ≥1 at baseline whose disease then progressed would be considered an incident case, although really they should be considered “progressors.” Indeed, when we compared IL-6 levels according to K/L grade (unaffected = K/L grade <2, minor RKOA = K/L grade = 2, and severe RKOA = K/L grade >2), a consistent association of continuous increases in these parameters was observed (Figure 1), which was consistent with the ORs for RKOA by quartiles of IL-6 levels. Similarly, if we had used magnetic resonance imaging or another more sensitive measure of disease, then most incident cases would probably be those with minor OA detectable at baseline. Clearly, the study would have benefited from current radiologic standards and techniques for the knee, although any misclassification due to the extended knee position would have acted to obscure the results.

It is also important to note that this study did not examine the effect of OA comorbidity in the other joints. This would lead to a much more complex analysis of the data, which was beyond the scope of this study.

A further, minor limitation is that the study was undertaken using data only from female subjects. OA is increasingly recognized to be site- and sex-specific, and therefore the present results may not be directly extrapolated to men. There is little evidence, however, to suggest that cytokine expression differs significantly between the sexes.

In conclusion, the present findings suggest that a higher BMI and increased circulating levels of IL-6 are associated with the development of RKOA. IL-6 is therefore a potential new biomarker for OA development and may provide useful information in the prediction of disease outcome. Moreover, highlighting the potential key role of IL-6 in the disease process may lead to studies of IL-6 blockade as a therapeutic strategy in OA.
ACKNOWLEDGMENTS

We are thankful to David Doyle, Alan Hakim, and the staff and volunteers of the Chingford Study.

AUTHOR CONTRIBUTIONS

All authors were involved in drafting the article or revising it critically for important intellectual content, and all authors approved the final version to be published. Dr. Spector had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Study conception and design. Livshits, Zhai, Spector.

Acquisition of data. Wang, Spector.

Analysis and interpretation of data. Livshits, Hart, Kato, Williams.

REFERENCES

1. WHO Scientific Group on the Burden of Musculoskeletal Conditions at the Start of the New Millennium. The burden of musculoskeletal conditions at the start of the new millennium. World Health Organ Tech Rep Ser 2003;919;i-x, 1–218. back cover.
2. Reginster JY. The prevalence and burden of arthritis. Rheumatology (Oxford) 2002;41:3–6.
3. Katz JN. Total joint replacement in osteoarthritis. Best Pract Res Clin Rheumatol 2006;20:145–53.
4. Penninx BW, Kritchevsky SB, Newman AB, Nicklas BJ, Simonsick EM, Rubin S, et al. Inflammatory markers and incident mobility limitation in the elderly. J Am Geriatr Soc 2004;52:1105–13.
5. Park HS, Park JY, Yu R. Relationship of obesity and visceral adiposity with serum concentrations of CRP, TNF-a and IL-6. Diabetes Res Clin Pract 2005;69:29–35.
6. Miller GD, Nicklas BJ, Locser RF. Inflammatory biomarkers and physical function in older, obese adults with knee pain and self-reported osteoarthritis after intense weight-loss therapy. J Am Geriatr Soc 2008;56:644–51.
7. Bullo M, Garcia-Lorda P, Megias I, Salas-Salvado J. Systemic inflammation, adipose tissue tumor necrosis factor, and leptin expression. Obes Res 2003;11:525–31.
8. Buteiner B, Cerami A. Cachectin (tumor necrosis factor): a macrophage hormone governing cellular metabolism and inflammatory response. Endocr Rev 1988;9:57–66.
9. Tracey KJ, Vlassara H, Cerami A. Cachectin/tumor necrosis factor. Lancet 1989;1:1122–6.
10. Dinarello CA, Wolff SM. The role of interleukin-1 in disease. N Engl J Med 1993;328:106–13.
11. Fisher AL. Of worms and women: sarcopenia and its role in disability and mortality. J Am Geriatr Soc 2004;52:1185–90.
12. Tsujinaka T, Fujita J, Ebisu C, Yano M, Kominami E, Suzuki K, et al. Interleukin-6 receptor antibody inhibits muscle atrophy and modulates proteolytic systems in interleukin 6 transgenic mice. J Clin Invest 1996;97:244–9.
13. Kwan Tat S, Padrones M, Theoleyre S, Heymann D, Fortun Y. IL-6. RANKL. TNF-a/IL-1: interrelations in bone resorption pathophysiology. Cytokine Growth Factor Rev 2004;15:49–60.
14. Aderka D, Le JM, Vilecek J. IL-6 inhibits lipopolysaccharide-induced tumor necrosis factor production in cultured human monocytes, U937 cells, and in mice. J Immunol 1989;143:3517–23.
15. Cesari M, Penninx BW, Pahor M, Lauretani F, Corsi AM, Rhys Williams G, et al. Inflammatory markers and physical performance in older persons: the InCHIANTI study. J Gerontol A Biol Sci Med Sci 2004;59:A242–7.
16. Spector TD, Hart DJ, Nandra D, Doyle DV, Mackillop N, Gallimore JR, et al. Low-level increases in serum C-reactive protein are present in early osteoarthritis of the knee and predict progressive disease. Arthritis Rheum 1997;40:723–7.
17. Goldring MB, Goldring SR. Osteoarthritis. J Cell Physiol 2007;213:626–34.
18. Pearl AE, Scanzello CR, George S, Mandl LA, DiCarlo EF, Peterson M, et al. Elevated high-sensitivity C-reactive protein levels are associated with local inflammatory findings in patients with osteoarthritis. Osteoarthritis Cartilage 2007;15:516–23.
19. Engstrom G, Gerhardsson de Verdier M, Rollof J, Nilsson PM, Lohmander LS. C-reactive protein, metabolic syndrome and incidence of severe hip and knee osteoarthritis: a population-based cohort study. Osteoarthritis Cartilage 2008. E-pub ahead of print.
20. Dolan AL, Hart DJ, Doyle DV, Grahame R, Spector TD. The relationship of joint hypermobility, bone mineral density, and osteoarthritis in the general population: the Chingford study. J Rheumatol 2003;30:799–803.
21. Zhai G, Hart DJ, Valdes AM, Kato BS, Richards JB, Hakim A, et al. Natural history and risk factors for bone loss in postmenopausal Caucasian women: a 15-year follow-up population-based study. Osteoporos Int 2008;19:1211–17.
22. Kellgren JH, Lawrence JS. Radiological assessment of osteoarthritis. Ann Rheum Dis 1957;16:494–502.
23. Rabes-Hesketh S, Skrondal A. Multilevel and longitudinal modeling using Stata. 2nd ed. College Station (TX): Stata Press; 2008.
24. Felson DT. Clinical practice: osteoarthritis of the knee [published erratum appears in N Engl J Med 2006;354:2520]. N Engl J Med 2006;354:841–8.
25. Ayral X, Pickering EH, Woodworth TG, Mackillop N, Dougados M. Synovitis: a potential predictive factor of structural progression of medial tibiofemoral knee osteoarthritis: results of a 1-year longitudinal arthroscopic study in 422 patients. Osteoarthritis Cartilage 2005;13:361–7.
26. Goldring MB, Otero M, Tsuchimochi K, Iijiri K, Li Y. Defining the roles of inflammatory and anabolic cytokines in cartilage metabolism. Ann Rheum Dis 2008;67 Suppl 3:iii75–82.
27. Sturmer T, Brenner H, Koenig W, Gunther KP. Severity and extent of osteoarthritis and low grade systemic inflammation as assessed by high sensitivity C reactive protein. Ann Rheum Dis 2004;63:200–5.
28. Nathan C. Epidemic inflammation: pondering obesity. Mol Med 2008;14:485–92.
29. Das UN. Is obesity an inflammatory condition? Nutrition 2001;17:953–6.
30. Carman WJ, Sowers M, Hawthorne VM, Weissfeld LA. Obesity as a risk factor for osteoarthritis of the hand and wrist: a prospective study. Am J Epidemiol 1994;39:119–29.